Trial Profile
A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 14 Sep 2021 Status changed from active, no longer recruiting to completed.
- 02 Oct 2020 Planned End Date changed from 1 Jun 2018 to 1 Jun 2021.
- 02 Oct 2020 Status changed from discontinued to active, no longer recruiting.